Significats de atomoxetine en anglès

Results: Behaviorally, atomoxetine led to a significant increase in failed inhibition.

In general, d-amphetamine increases risk-taking while atomoxetine has produced mixed effects in rats.

There were no significant improvements while on atomoxetine compared with placebo on primary outcomes.

There were no serious adverse events related to atomoxetine.

Effects of d-amphetamine on probabilistic discounting may be biology-dependent and differ from effects of atomoxetine.

In addition, atomoxetine tended to reduce reaction time variability.

Adults with narrow-angle glaucoma should not use atomoxetine.

A total of 921 children and adolescents with ADHD participated in a clinical study of atomoxetine.

Conclusion: This study demonstrated no increase in the risk of sudden death associated with stimulants or atomoxetine.

Especially the increased expression of SNAP-25 and GABA-A receptor subunits may indicate additional active therapeutic mechanisms for atomoxetine.

We found that atomoxetine increased the subject's perceptual sensitivity to discriminate target stimuli regardless of the task contingency.

In this study, we evaluated dose-dependent effects of d-amphetamine and atomoxetine on probabilistic discounting of Lewis and F344.

Sudden cardiac death has occurred in children and adults taking atomoxetine; it increases heart rate and blood pressure significantly.

Although atomoxetine was not effective at improving attention at this dose, its safety and tolerability were similar to other studies.

We investigated the effects of atomoxetine (80 mg) on error monitoring as a second key component of cognitive control.

The objective of this animal study was to determine alterations in gene expression patterns in the prefrontal cortex after long-term administration of atomoxetine.